Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy
- Lunit to support MD Anderson researchers studying immune phenotype biomarkers for pembrolizumab treatment response SEOUL, South Korea, Oct. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...
Lunit Participates in Saudi Vision 2030 Healthcare Sandbox, Accelerating Saudi Arabia's Healthcare Transformation
* Memorandum of Understanding to be inked between Lunit and Seha Virtual Hospital, marking a new era inSaudi Arabia's healthcare innovation movement SEOUL, South Korea, Oct. 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and th...
First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO - newly published in JCO
* Lunit SCOPE IO pivotal in first phase III trial successfully showing the efficacy of immunotherapy + chemotherapy for NSCLC patients with EGFR or ALK mutation - published in theJournal of Clinical Oncology and accepted by ESMO for oral presentation SEOUL, South Korea, Oct. 24, 2023 /PRNewswir...
New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023
- Nine abstracts, featuring the effectiveness of Lunit's AI-powered TIL/WSI analyzer and biomarker platform, accepted by the ESMO 2023 Congress SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeut...
Lunit to Showcase 9 AI-based Research Results at ESMO 2023
- 9 abstracts accepted by the ESMO annual meeting - unveiling insights into cancer analysis, immunotherapy response, and predictive biomarkers at ESMO 2023 SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics an...
Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting
- Lunit's 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SCOPE across diverse cancer types at SITC 2023 SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeu...
Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening
* Lunit's collaborative study supports AI as a viable alternative to one human reader inEurope's double reading system - published in The Lancet Digital Health SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagno...
Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening
- Lunit's collaborative study supports AI as a viable alternative to one human reader inEurope's double reading system - published in The Lancet Digital Health SEOUL, South Korea, Sept. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnosti...
Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment - to be presented at WCLC 2023
- A collaborative study demonstrates that AI analysis of Tertiary Lymphoid Structures (TLS) in tumors can predict treatment response in non-small cell lung cancer patients SEOUL, South Korea, Aug. 21, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for canc...
Lunit Presents Groundbreaking Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer
- Collaborative study with NCCHE shows that AI analysis of HER2 expression and the tumor microenvironment is linked to treatment response of Pertuzumab+Trastuzumab in colorectal cancer SEOUL, South Korea, Aug. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered soluti...
Lunit Accelerates Expansion Across Middle East by Bringing AI Solution to Dr. Sulaiman Al Habib Medical Group, Middle East's Largest Healthcare Provider
Lunit strengthens presence in the Middle East by supplying AI-powered breast screening solution to Dr. Sulaiman Al Habib Medical Group for the next three years SEOUL, South Korea, July 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnosti...
Lunit Makes Full-Fledged Entry into the Middle East with Participation in 'Saudi Vision 2030' Healthcare Transformation Project
* Lunit's AI-powered cancer screening solutions have been selected for Seha Virtual Hospital's AI evaluation and clinical integration project * Successful validation to be followed by supply contract to assist Saudi Arabia's national cancer and tuberculosis screening program SEOUL, South Korea...
Lunit's AI-Powered Lung Cancer Screening Solution Significantly Affects Radiologists' Diagnostic Determination - Published in Radiology
- Recent study conducted by Seoul National University Hospital provides strong evidence that high-accuracy AI model improves radiologists' chest X-ray analysis performance SEOUL, South Korea, July 3, 2023 /PRNewswire/ -- Findings from a recent study demonstrate that medical AI solutions with onl...
CXR-AID, Powered by Lunit, Nets Japan Nod for Reimbursement, Accelerating Market Expansion Opportunities
- Medical AI solutions, including CXR-AID, officially included in Japanese health insurance reimbursement as a management service fee of imaging diagnosis SEOUL, South Korea, June 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of cancer diagnostics solutions, today announced th...
Breakthrough AI Research by Lunit Presented at CVPR 2023: Transforming Pathology with Computer Vision for Medical Applications
- Lunit's pioneering AI study to be unveiled at one of the premier computer vision conferences, innovating pathology with more accurate cell detection SEOUL, South Korea, June 12, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer diagnostic solutions, toda...
Lunit and Capio S:t Göran Hospital Collaborate to Address Radiologist Shortage with AI-Powered Mammography Analysis
- Lunit and Sweden's largest private hospital pioneering a new approach to combine radiologists' expertise with AI SEOUL, South Korea, June 5, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer diagnostic solutions, today announced the signing of a supply ...
Lunit and the Japan National Cancer Center Hospital East Partner in AI Pathology to Advance Precision Oncology
* Collaborative research with Japan's largest oncology practice shows Lunit SCOPE's potential in predicting clinical outcomes for rectal cancer SEOUL, South Korea, May 30, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global provider of AI-powered cancer diagnostic solutions, today announced c...
Lunit Demonstrates Predictive Value of AI-Biomarker Platform at the 2023 ASCO Annual Meeting
- New studies reveal Lunit SCOPE's impact on predicting clinical outcomes, analyzing tumor microenvironment, and enhancing personalized cancer treatment SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global leader of AI-powered cancer diagnostics and therapeutics soluti...
Lunit to Present 16 Abstracts at the 2023 ASCO Annual Meeting
- Lunit and collaborators demonstrate the predictive value and analytical prowess of Lunit's AI-biomarker platform in a wide range of cancer types and clinical practices SEOUL, South Korea, May 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading global provider of AI-powered cancer di...
Lunit Demonstrates Progress in the Development of Novel Diagnostics at the 2023 AACR Annual Meeting
* Lunit and collaborators demonstrate key progress in the development of novel diagnostics for cancer therapies, including immuno-oncology, in addition to molecular targeted agents and antibody-drug conjugates * Presentations to deliver new research using Lunit SCOPE in a wide range of cancer...
